Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 4226 - 4250 of 4264 in total
Morus alba root bark is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Investigational
C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.
Investigational
Azelnidipine is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan. It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers . It is currently being...
Investigational
Cofirasersen is under investigation in clinical trial NCT04441788 (A Study to Assess the Safety, Tolerability, and Efficacy of ION-827359 in Participants With Mild to Moderate Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis (CB)).
Investigational
Investigational
Experimental
Pemlimogene merolisbac is under investigation in clinical trial NCT03371381 (An Efficacy and Safety Study of JNJ-64041757, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Nivolumab Versus Nivolumab Monotherapy in Participants With Advanced Adenocarcinoma of the Lung).
Investigational
Zelpultide alfa is a recombinant human surfactant protein D.
Investigational
Displaying drugs 4226 - 4250 of 4264 in total